Ken Griffin Pro Phase Labs, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$4.47 - $6.47 $10,728 - $15,528	2,400 New	2,400 $15,000
Q3 2023 Nov 14, 2023	SELL	$4.23 - $7.53 $10,998 - $19,578	-2,600 Reduced 18.18%	11,700 $51,000
Q2 2023 Aug 14, 2023	BUY	$7.15 - $9.78 $41,470 - $56,723	5,800 Added 68.24%	14,300 $103,000
Q1 2023 May 15, 2023	SELL	$6.62 - $9.57 $1,324 - $1,914	-200 Reduced 2.3%	8,500 $64,000
Q4 2022 Feb 14, 2023	BUY	$8.78 - $12.47 $76,386 - $108,489	8,700 New	8,700 $83,000

1.66M

2.4K

Ticker PRPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 16,024,400
Market Cap $60.9M
Description
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.